TD Private Client Wealth’s Amicus Therapeutics FOLD Stock Holding History

TD Private Client Wealth’s Portfolio FOLD Stock Details FOLD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-42	Closed	-$401	–	1200
2021 Q3	$401	Hold	42	–	–	﹤0.01%	1188
2021 Q2	$405	Hold	42	–	–	﹤0.01%	1196
2021 Q1	$415	Hold	42	–	–	﹤0.01%	1143
2020 Q4	$970	Hold	42	–	–	﹤0.01%	1021
2020 Q3	$593	Hold	42	–	–	﹤0.01%	1015
2020 Q2	$633	Hold	42	–	–	﹤0.01%	1002
2020 Q1	$388	Hold	42	–	–	﹤0.01%	989
2019 Q4	$409	Buy	+42	New	+$384	﹤0.01%	1010

Other funds holding FOLD

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

TD Private Client Wealth's FOLD Position: Q4 2021 in Review

TD Private Client Wealth sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 42 shares — an estimated $401 sold.

TD Private Client Wealth first reported a position in FOLD in Q4 2019 and held it in 8 quarters. The position peaked at $970 in Q4 2020. 223 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

TD Private Client Wealth reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
TD Private Client Wealth sold 42 Amicus Therapeutics shares in Q4 2021, an estimated $401.
TD Private Client Wealth first reported a position in Amicus Therapeutics in Q4 2019 and held it in 8 quarters.
TD Private Client Wealth's Amicus Therapeutics position peaked at $970 in Q4 2020.
223 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on TD Private Client Wealth's 13F filing for Q4 2021, filed 16 Aug 2024.